1213 / 1631
Two years Rituximab maintenance vs. observation after
first line treatment with Bendamustine plus Rituximab
in patients with Marginal Zone Lymphoma (MZL):
results from the StiL NHL7-2008
M
AINTAIN
trial
Results of a prospective, randomized, multicentre phase 2 study
(a subgroup study of the StiL NHL7-2008
M
AINTAIN
trial)
Mathias Rummel
, Michael Koenigsmann, Kai Chow, Wolfgang
Knauf, Christian A. Lerchenmuller, Christoph Losem, Martin
Goerner, Bernd Hertenstein, Thomas Decker, Arnold Ganser,
Tobias Gaska, Mich. Heike, Elisabeth Lange, Rudolf Weide,
Wolfgang Willenbacher, Alexander Burchardt, Frank Kauff,
Juergen Barth, Axel Hinke, Richard Greil on behalf of the
StiL
Study group indolent Lymphomas,
Austria and Germany